ArticleClinical and experimental medicine2025
The application performance of MRI-PDFF detection values of different hepatic lobes in diagnosing liver steatosis.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Diagnostic Performance of Ultrasound-Guided Attenuation Parameter (UGAP) for Hepatic Steatosis Assessment: Comparison with MRI-PDFF and Evaluation of Cohort-Derived Thresholds.Diagnostics (Basel, Switzerland) · 2026Article
- Hepatic fat fraction and lipid content of adrenal adenomas: insights from unenhanced CT.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Magnetic resonance imaging derived proton density fat fraction (MRI-PDFF) is becoming increasingly important for assessing liver steatosis, which is traditionally diagnosed via liver biopsy. In the present study, we aimed to evaluate the efficacy of MRI-PDFF in detecting liver steatosis by comparing its values from various liver lobes-the right posterior hepatic lobe (RPHL), right anterior hepatic lobe (RAHL), left inner hepatic lobe (LIHL), left outer hepatic lobe (LOHL), the mean value of four hepatic lobes (M-PDFF), and the highest value of four hepatic lobes (H-PDFF)-against biopsy results. The findings indicated that MRI-PDFF exhibited strong performances in identifying liver steatosis in 125 patients, with area under the receiver operating characteristic (AUROC) values of 0.870 for RPHL, 0.875 for RAHL, 0.881 for LIHL, 0.871 for LOHL, 0.881 for M-PDFF, and 0.878 for H-PDFF. Furthermore, MRI-PDFF demonstrated significant advantages in detecting moderate-to-severe steatosis, achieving AUROC values of 0.897 for RPHL, 0.911 for RAHL, 0.905 for LIHL, 0.898 for LOHL, 0.907 for M-PDFF, and 0.904 for H-PDFF. Overall, MRI-PDFF is a highly accurate and noninvasive tool for diagnosing liver steatosis and determining its severity, making it valuable for clinical assessment and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.